Science selects Renakapavir 'Innovation of the Year' for preventing HIV infection for 6 months with a single shot
Dec 13, 2024
Science, a global scientific journal, has selected lenacapavir (lenacapavir), a groundbreaking HIV infection treatment, and related studies for the '2024 Innovation of the Year'.
Renacapavir, an anti-retroviral drug developed by Gilead, is an injection that prevents human immunodeficiency virus (HIV) infection for six months with a single dose.
Science explained that the drug was 100% preventive in clinical trials for African adolescent girls and women and 99.9% in various genders on multiple continents. He also said that the secret to this effect came from groundbreaking research on HIV's capsid protein, which protects viral genetic material. Renacapavir acts as a mechanism to block the major steps in viral replication by hardening capsid proteins. Such a mechanism was once considered impractical, but the success of renacapavir is expected to inspire the treatment of other viral diseases.
Science explained that lenacapavir was initially developed as a rescue therapy for patients who developed resistance to other drugs, but lenacapavir, which was developed in the form of a long-lasting injection, has now established itself as a drug that can be a game changer in HIV prevention.
Meanwhile, Renacapavir is expected to be approved by regulatory authorities such as the U.S. Food and Drug Administration (FDA) by next year.
Renacapavir, an anti-retroviral drug developed by Gilead, is an injection that prevents human immunodeficiency virus (HIV) infection for six months with a single dose.
Science explained that the drug was 100% preventive in clinical trials for African adolescent girls and women and 99.9% in various genders on multiple continents. He also said that the secret to this effect came from groundbreaking research on HIV's capsid protein, which protects viral genetic material. Renacapavir acts as a mechanism to block the major steps in viral replication by hardening capsid proteins. Such a mechanism was once considered impractical, but the success of renacapavir is expected to inspire the treatment of other viral diseases.
Science explained that lenacapavir was initially developed as a rescue therapy for patients who developed resistance to other drugs, but lenacapavir, which was developed in the form of a long-lasting injection, has now established itself as a drug that can be a game changer in HIV prevention.
Meanwhile, Renacapavir is expected to be approved by regulatory authorities such as the U.S. Food and Drug Administration (FDA) by next year.
compact@sportschosun.com
